2.105

2.44% 0.055

Allogene Therapeutics Inc (ALLO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.05

Offen:

$2.06

24-Stunden-Volumen:

1.31M

Relative Volume:

0.64

Marktkapitalisierung:

$435.07M

Einnahmen:

$95,000

Nettoeinkommen (Verlust:

$-327.27M

KGV:

-0.8592

EPS:

-2.45

Netto-Cashflow:

$-239.25M

1W Leistung:

-14.63%

1M Leistung:

-25.00%

6M Leistung:

-21.93%

1J Leistung:

-25.53%

1-Tages-Spanne:

$2.005

$2.14

1-Wochen-Bereich:

$1.99

$2.52

52-Wochen-Spanne:

$1.99

$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Firmenname

Allogene Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(650) 457-2700

Adresse

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Mitarbeiter

361

Twitter

@AllogeneTx

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ALLO's Discussions on Twitter

Vergleichen Sie ALLO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALLO	2.10	435.07M	95,000	-327.27M	-239.25M	-2.45
VRTX	450.44	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	749.43	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	589.59	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.53	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.84	24.89B	3.30B	-501.07M	1.03B	11.54

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-05	Herabstufung	Guggenheim	Buy → Neutral
2024-01-05	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Eingeleitet	Citigroup	Buy
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-01-24	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-06	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-12-12	Herabstufung	BofA Securities	Buy → Underperform
2022-08-10	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-07-15	Hochstufung	Goldman	Neutral → Buy
2022-06-03	Eingeleitet	Robert W. Baird	Neutral
2022-02-28	Bestätigt	B. Riley Securities	Buy
2021-10-20	Eingeleitet	Cowen	Outperform
2021-10-08	Herabstufung	Goldman	Buy → Neutral
2021-10-08	Herabstufung	Stifel	Buy → Hold
2021-09-23	Hochstufung	Raymond James	Mkt Perform → Outperform
2021-06-21	Fortgesetzt	Jefferies	Buy
2021-05-20	Hochstufung	Truist	Hold → Buy
2021-05-14	Eingeleitet	B. Riley Securities	Buy
2021-01-26	Hochstufung	Stifel	Hold → Buy
2020-12-10	Fortgesetzt	H.C. Wainwright	Buy
2020-11-24	Eingeleitet	BofA Securities	Buy
2020-10-23	Eingeleitet	RBC Capital Mkts	Outperform
2020-06-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-29	Bestätigt	H.C. Wainwright	Buy
2020-05-19	Hochstufung	ROTH Capital	Neutral → Buy
2020-05-15	Hochstufung	Guggenheim	Neutral → Buy
2020-05-14	Bestätigt	H.C. Wainwright	Buy
2020-05-14	Herabstufung	SunTrust	Buy → Hold
2020-04-13	Eingeleitet	SunTrust	Buy
2020-03-13	Eingeleitet	H.C. Wainwright	Buy
2020-03-05	Eingeleitet	Stifel	Hold
2020-02-24	Eingeleitet	Berenberg	Hold
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-11-04	Eingeleitet	Canaccord Genuity	Buy
2019-08-09	Eingeleitet	BTIG Research	Buy
2019-06-05	Eingeleitet	ROTH Capital	Neutral
2019-05-31	Eingeleitet	Guggenheim	Neutral
2019-05-23	Eingeleitet	Stifel	Hold
2019-03-29	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten

Nov 20, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewswire

Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024

Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024

Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024

Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024

Nov 10, 2024

Allogene Therapeutics Q3 2024 Earnings Preview - MSN

Nov 10, 2024

Nov 09, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com

Nov 08, 2024

Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024